Alnylam's drug vutrisiran meets primary endpoint in ATTR amyloidosis with cardiomyopathy study, reducing death and hospitalizations.

Alnylam Pharmaceuticals' drug, vutrisiran (Amvuttra), met its primary endpoint in a late-stage study, showing a 28% and 33% reduction in death and hospitalizations in patients with ATTR amyloidosis with cardiomyopathy. The company plans to file global regulatory submissions starting later this year, including a supplemental New Drug Application to the FDA seeking priority review. Shares of Alnylam surged over 37% in pre-market trading.